Abstract Body

To eliminate HBV infectious complete suppression of progeny virus coordinate with the elimination of infected cells must be achieved.  These events can be facilitated by enhancing innate and adaptive immune responses given with antiviral therapy. We offer a new therapeutic prospective by increasing  the potency of nitazoxanide (NTZ), a broad-spectrum antiviral and immune stimulating agent and tenofovir (TFV), a nucleoside reverse transcriptase inhibitor. This drug combination was transformed into hydrophobic prodrug nanocrystals, then stabilized into aqueous nanosuspensions. The modifications led to extended apparent drug half-lives, increased drug potency and improved distribution to liver cell viral compartments.

NTZ and TFV prodrugs (M1NTZ and M1TAF) were synthesized and nanoformulated creating NM1NTZ and NM1TAF. Cellular drug uptake and retention was determined in human monocyte-derived macrophages (MDM). The HBV-producing human hepatocellular carcinoma HepG2.2.15 cell and humanized liver TK-NOG mice evaluated antiviral activity. HBV infected mice received a single 75 mg/kg intramuscular injection of the drugs. HBV DNA, cccDNA and HBe/sAg were monitored for 48 h and for 10 weeks in cells and animals, respectively.  

NM1NTZ and NM1TAF had average particle sizes of 250-350 nm, polydispersity index of <0.2 and drug loading capacity of > 70%. Both formulations were taken up by MDM with sustained drug levels for 30 days; whereas native drugs were eliminated in one day. Suppression of HBV DNA release by (NM1TAF by 50%) and cccDNA pools (NM1NTZ  by 88% and NM1TAF by 60%) were recorded. The combination long acting prodrug therapy reduced HBV DNA in plasma of humanized mice to undetectable levels in 2/4 animals tested at four weeks with readily detected human cells (Fig). The remaining two animals showed > log decrease in plasma viral load at equivalent times. Animals were monitored for 10 weeks to measure viral rebound. 

Long-acting TFV and NTZ prodrugs sustained antiviral activity in humanized mice for a month after a single dose. These data sets support the potential of monthly NM1TAF and NM1NTZ dosing for treatment of HBV infections.